Cerebrolysin Research Overview (also known as FPF 1070, Cerebrolysin complex, Porcine brain hydrolysate, CERE)
A neuropeptide preparation composed of low-molecular-weight peptides and amino acids derived from purified porcine brain protein. Studied for its neurotrophic, neuroprotective, and neuroregenerative properties in research including traumatic brain injury recovery, neurodegenerative disease models, neuroplasticity support, and cognitive function enhancement.
For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Cerebrolysin?
Cerebrolysin is a parenterally administered neuropeptide preparation derived from pig brain tissue through controlled enzymatic proteolysis. It is a mixture of small bioactive peptides (molecular weight below 10,000 Da) and free amino acids that together produce neurotrophic effects similar to endogenous NGF, BDNF, CNTF, and other neurotrophins. It is approved for clinical use in cognitive disorders and stroke recovery in over 40 countries.
Mechanism of Action
Cerebrolysin produces its effects through multiple mechanisms: it mimics endogenous neurotrophic factors by activating TrkA, TrkB, and p75NTR receptors on neurons; reduces excitotoxic glutamate signaling; protects neurons from oxidative stress; and promotes neuroplasticity by stimulating synaptogenesis and dendritic arborization. Its peptide fractions can cross the blood-brain barrier, allowing systemic administration to produce central neurotrophic effects.
Clinical Evidence
Multiple RCTs have demonstrated improvements in global clinical status, cognition, and ADL function in mild-to-moderate Alzheimer's patients. In stroke, the CASTA trial documented improvements in early neurological recovery. These represent some of the most robust clinical datasets for any neurotrophic peptide preparation.
Quick Reference
| Literature-Reported Dose Range | 5–10 mL |
| Literature-Reported Frequency | Once daily (acute) or 5 days weekly (chronic) |
| Literature-Reported Cycle Length | Acute: 7-30 days; Chronic: 4 weeks (2-4 cycles yearly) |
| Literature-Reported Washout | Cycles separated by 1-3 months for chronic conditions |
| Storage | Room temperature ≤25°C, protect from light, never freeze |
| Sites Reported in Studies | IV: up to 10mL direct, IM: up to 5mL (larger volumes require infusion) |
| Timing | As soon as possible for acute conditions; morning preferred |
Research Indications
Cognitive
Alzheimer's Disease - Mixed Evidence
Meta-analyses show modest cognitive improvements, though clinical significance remains debated in medical literature
Vascular Dementia - Established Efficacy
Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements with well-documented protocols
Post-Stroke Cognitive Recovery
Large meta-analysis shows significant NIHSS improvements, though other studies found no functional benefit
Neuroprotection
Acute Stroke - Evidence Mixed
Largest meta-analysis (1,879 patients) shows NIHSS benefits, but independent analysis found no mRS/BI improvement
Traumatic Brain Injury - Strong Evidence
Multiple trials including CAPTAIN series and large systematic review confirm GCS/GOS improvements
Subarachnoid Hemorrhage - Emerging Evidence
Pilot trial shows promising 6-month outcomes, but requires larger confirmatory studies
Recovery
Motor Function Recovery - Variable Results
Some studies show enhanced motor recovery, but results vary significantly between trials
Neurological Function - Time-Dependent
Early administration within 72 hours shows better outcomes than delayed treatment
Functional Independence - Limited Evidence
Some improvement in disability scales, though long-term functional benefits remain unclear
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Small Volume IV | Up to 10 mL | Once daily | Undiluted IV slow push over 3 minutes |
| Intramuscular | 5 mg - 25 mg | Once daily | Intramuscular (IM) |
| Acute Stroke | 20-50 mL | Once daily for 10-21 days | IV infusion (diluted to 100mL minimum) |
| Traumatic Brain Injury | 20-50 mL | Once daily for 7-30 days | IV infusion (diluted to 100mL minimum) |
| Alzheimer's Disease | 10-30 mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
| Vascular Dementia | 10-30 mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
Timing
Recommended administration window: as soon as possible for acute conditions; morning preferred. Typical onset: acute: 24-72 hours; Cognitive: 2-4 weeks; Full recovery: 4-12 weeks.
Peptide Interactions
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
Safe combination demonstrated in clinical studies with no significant interactions. Both compounds work through different mechanisms to support cognitive function.
No significant interactions reported. May have synergistic cognitive effects when used together in Alzheimer's treatment protocols.
Potential additive neurotropic effects. Monitor for enhanced antidepressant effects and consider dose adjustment if combining long-term.
May have additive neurological effects. Requires careful monitoring and potential dose adjustments of antidepressant medications.
Not Recommended per official prescribing information. Cerebrolysin should not be mixed with balanced amino acid solutions in same infusion.
Official prescribing information states Cerebrolysin should not be mixed with cardiovascular medicinal products in same infusion.
Per official guidelines, Cerebrolysin should not be mixed with vitamin solutions in same IV infusion due to compatibility issues.
Both enhance BDNF and affect glutamatergic signaling. Cerebrolysin contains neurotrophic peptides, Noopept modulates AMPA/NMDA receptors. Potential for additive cognitive effects - start with lower doses when combining and monitor for overstimulation.
Reported Research Timeline
01Weeks 1–2 (reported in cited studies): neuroprotective cascade initiates; some researchers note mild transient effects (dizziness, sleep changes) as the brain responds.
02Weeks 2–4 (reported in cited studies): cognitive improvements become measurable in most studies. Memory, attention, and executive function begin to surface in vascular dementia and Alzheimer’s trial data.
03Weeks 4–8 (reported in cited studies): continued recovery in stroke and TBI rehabilitation models; motor function and daily functioning improvements in chronic condition trials.
04Weeks 8–12 (reported in cited studies): benefits plateau and are maintained. Signal to enter an off-cycle before reassessing whether another course is warranted.
Side effects (reported in cited studies): usually minimal at standard doses
Most common (reported in cited studies): injection-site reactions; transient dizziness
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Monitor for allergic reactions during first administration - generally well tolerated
Not Recommended in epilepsy and severe renal insufficiency per official prescribing information
Clinical evidence shows mixed results - some large studies positive, others neutral
Research integrity concerns have been raised about some published studies
Not approved in USA but used clinically in over 50 countries worldwide
Use disposable one-way infusion sets to guarantee sterility
Seek Medical Attention If:
Severe allergic reactions (anaphylaxis, severe rash)
New onset seizure activity (contraindicated in epilepsy)
Significant cardiovascular events during administration
Severe renal dysfunction or worsening kidney function
Quality Indicators
Verified Marker
Clear amber solution from reputable source
Cerebrolysin should be clear amber colored without particles. Ensure sourcing from authorized EVER Pharma distributors
Verified Marker
Room temperature storage ≤25°C as specified
Store at room temperature per official prescribing information, never freeze
Verified Marker
Protected from light
Stored in original carton to protect from light exposure
Verified Marker
Clinical evidence awareness
Be aware that research shows mixed results - some large studies positive, others neutral
Acceptable Range
Research quality considerations
Some published studies have been retracted due to research misconduct - rely on independent meta-analyses
Quality Concern
Frozen product or improper storage
Never freeze Cerebrolysin - freezing damages peptide structure and renders product ineffective
Quality Concern
Mixing with incompatible solutions
Do not mix with amino acid solutions, vitamins, or cardiovascular medications per official guidelines
Research Citations
- Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials
Bornstein, N.M., Guekht, A., Vester, J., et al., 2018, Neurological Sciences - How to use Cerebrolysin®
Ever Pharma, N/A, N/A - Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials
Zhang, D., Dong, Y., Li, Y., et al., 2017, BioMed Research International - Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial
Muresanu, D.F., Heiss, W.D., Hoemberg, V., et al., 2020, Neurological Sciences - Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis
Kojder, K., Sykutera, M., Gold, P., et al., 2023, Brain Sciences - Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage
Woo, P.Y.M., Ho, J.W.K., Tse, T.P.K., et al., 2020, BMC Neurology - Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials
Gauthier, S., Proano, J.V., Jia, J., et al., 2015, Dementia and Geriatric Cognitive Disorders - Cerebrolysin for vascular dementia
Cui, S., Cui, L., Mutz, J., et al., 2019, Cochrane Database of Systematic Reviews - Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes
Fiani, B., Barthelmass, E., Bosco, A., et al., 2021, Neurological Sciences - Efficacy, safety, and cost-effectiveness analysis of Cerebrolysin in acute ischemic stroke: A rapid health technology assessment
Li, J., Yu, Q., Zhang, L., et al., 2024, Medicine (Baltimore) - Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial
Guekht, A.B., Moessler, H., Novak, P.H., et al., 2011, Journal of Stroke and Cerebrovascular Diseases
Research Focus
Neuroprotection, Alzheimer's disease, Stroke recovery, Traumatic brain injury, Cognitive enhancement, BDNF
Verified Vendors Carrying Cerebrolysin
Frequently Asked Questions
What should researchers watch for with Cerebrolysin?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Cerebrolysin?
Weeks 1–2 (reported in cited studies): neuroprotective cascade initiates; some researchers note mild transient effects (dizziness, sleep changes) as the brain responds.
How is Cerebrolysin typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →